For U.S. Healthcare Professionals Only

For Healthcare Professionals

Aggressively treat AKs...


  • 60% of SCCs arise from a previously existing AK lesion1
    • AK Lesion - Squamous Cancer Cell
    Carac® is not indicated for the treatment of SCCs.

...with powerful lesion reduction


  • Rapid efficacy — nearly 70% reduction in the number of AK lesions after 1 week of treatment2
  • Enduring efficacy — nearly 90% reduction in the number of AK lesions after 4 weeks of treatment2

Rapid efficacy that endures through treatment

Mean reduction in AK lesion counts:
1 week — -69.5%
2 weeks — -86.1%
4 weeks — -97.1%

Percent reduction based on least squares means of results from a vehicle-controlled, randomized, double-blind, multicenter study of patients (N=207) with AK (P<0.001 vs vehicle).*

Individual results may vary.

* A second vehicle-controlled, randomized, double-blind, multicenter study of patients (N=117) with AK showed the following reductions in the number of lesions: 78.5% after 1 week, 83.6% after 2 weeks, and 88.7% after 4 weeks (P<0.001 vs vehicle).9

Microsponge® is a registered trademark of Cardinal Health, Inc., its successors and assigns.

[Image of grass][Image of grass]
Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
IMPORTANT SAFETY INFORMATION
Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.
For more information, please see Full Prescribing Information for Carac®.